» Articles » PMID: 36650625

Evolution of Guideline Recommendations on Insulin Therapy in Type 2 Diabetes Mellitus Over the Last Two Decades: A Narrative Review

Overview
Specialty Endocrinology
Date 2023 Jan 17
PMID 36650625
Authors
Affiliations
Soon will be listed here.
Abstract

The prevalence of type 2 diabetes mellitus has been increasing worldwide. As the therapeutic options for type 2 diabetes mellitus have evolved over the last 2 decades, national and global guidelines related to type 2 diabetes mellitus pharmacotherapy issued by various organizations have tended to vary in their recommendations. This narrative review aimed to analyze the key recommendations by major global and national guidelines on the initiation of insulin therapy in patients with type 2 diabetes mellitus over the last 20 years. Strategies for insulin therapy for titration and intensification were also assessed. All guidelines recommend initiation of insulin (basal/ premixed/other formulations) when glycemic targets are not achieved despite lifestyle measures and oral antidiabetic drugs. In the recent decade, early initiation of insulin has been recommended when the glycated hemoglobin levels are >10% or blood glucose levels are ≥300 mg/dL (16.7 mmol/L). Initiation is recommended at a dose of 10 units or 0.1-0.2 U/kg. Titration is advised to achieve the optimal dosage, while intensification is recommended when glycemic targets are not achieved despite titrating to an acceptable level. Glucose monitoring at periodic intervals is recommended for adequate glycemic control. The guidelines further suggest that the choice of insulin should be individualized, considering the clinical status of patients with type 2 diabetes mellitus. The physicians as well as patients should be a part of the decisions made regarding the therapeutic choice of regimen, preparation, and delivery device.

Citing Articles

D.I.Ri.M.O. project: deprescription, inappropriateness evaluation and therapeutic reconciliation in hospital medicine.

Pollice M, Degli Esposti L, Procacci C, Lenti S, Ancona D, Nappi C Glob Reg Health Technol Assess. 2025; 12:61-69.

PMID: 40046609 PMC: 11880813. DOI: 10.33393/grhta.2025.3194.


Development and validation of a risk prediction model for PICC-related venous thrombosis in patients with cancer: a prospective cohort study.

Hu Z, Luo M, He R, Wu Z, Fan Y, Li J Sci Rep. 2025; 15(1):4654.

PMID: 39920370 PMC: 11805956. DOI: 10.1038/s41598-025-89260-1.


Astragalus polysaccharide attenuates diabetic nephropathy by reducing apoptosis and enhancing autophagy through activation of Sirt1/FoxO1 pathway.

Xu Y, Xu C, Huang J, Xu C, Xiong Y Int Urol Nephrol. 2024; 56(9):3067-3078.

PMID: 38653852 DOI: 10.1007/s11255-024-04038-0.


LIVE INDIA: Effectiveness of Gla-100 in a Post hoc Pooled Analysis of FINE ASIA and GOAL Registries.

Deshmukh V, Chaudhury T, Chadha M, Chawla M, Mukherjee S, Pitale S Diabetes Ther. 2023; 14(12):2075-2088.

PMID: 37789213 PMC: 10597908. DOI: 10.1007/s13300-023-01469-3.

References
1.
. 9. Pharmacologic Approaches to Glycemic Treatment: . Diabetes Care. 2018; 42(Suppl 1):S90-S102. DOI: 10.2337/dc19-S009. View

2.
. Standards of medical care in diabetes--2013. Diabetes Care. 2012; 36 Suppl 1:S11-66. PMC: 3537269. DOI: 10.2337/dc13-S011. View

3.
Garber A, Handelsman Y, Grunberger G, Einhorn D, Abrahamson M, Barzilay J . CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - . Endocr Pract. 2020; 26(1):107-139. DOI: 10.4158/CS-2019-0472. View

4.
Grant R, Kirkman M . Trends in the evidence level for the American Diabetes Association's "Standards of Medical Care in Diabetes" from 2005 to 2014. Diabetes Care. 2014; 38(1):6-8. DOI: 10.2337/dc14-2142. View

5.
. Standards of medical care in diabetes--2007. Diabetes Care. 2006; 30 Suppl 1:S4-S41. DOI: 10.2337/dc07-S004. View